Empirical data capturing participants’ experiences in preclinical Alzheimer's disease (AD) trials are limited. We examined participant responses on a Research Satisfaction Survey (RSS) from the Anti‐Amyloid Treatment in Asymptomatic AD Study.
Marina Ritchie, K. Hussen, O. Langford et al.· Alzheimer's & Dementia· 0 citations
Findings support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification and support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification.
T. Paranhos, Yuta Katsumi, M. Brickhouse et al.· Neurology· 0 citations
Higher plasma p-tau217 levels were consistently associated with increased risk of clinical progression and accelerated cognitive decline, and support the potential of p-tau217 for prognostic model development, with direct implications for future trial design.
R. Buckley, D. Townsend, C. Birkenbihl et al.· Journal of the American Medi...· 3 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
